| Literature DB >> 27476412 |
Nicholas J Barrows1, Rafael K Campos1, Steven T Powell2, K Reddisiva Prasanth2, Geraldine Schott-Lerner2, Ruben Soto-Acosta2, Gaddiel Galarza-Muñoz2, Erica L McGrath3, Rheanna Urrabaz-Garza4, Junling Gao3, Ping Wu3, Ramkumar Menon4, George Saade4, Ildefonso Fernandez-Salas5, Shannan L Rossi6, Nikos Vasilakis6, Andrew Routh7, Shelton S Bradrick8, Mariano A Garcia-Blanco9.
Abstract
Currently there class="Chemical">are no approved vaccines or class="Chemical">specific therapies to prevent or treat <class="Chemical">span class="Disease">Zika virus (ZIKV) infection. We interrogated a library of FDA-approved drugs for their ability to block infection of human HuH-7 cells by a newly isolated ZIKV strain (ZIKV MEX_I_7). More than 20 out of 774 tested compounds decreased ZIKV infection in our in vitro screening assay. Selected compounds were further validated for inhibition of ZIKV infection in human cervical, placental, and neural stem cell lines, as well as primary human amnion cells. Established anti-flaviviral drugs (e.g., bortezomib and mycophenolic acid) and others that had no previously known antiviral activity (e.g., daptomycin) were identified as inhibitors of ZIKV infection. Several drugs reduced ZIKV infection across multiple cell types. This study identifies drugs that could be tested in clinical studies of ZIKV infection and provides a resource of small molecules to study ZIKV pathogenesis.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27476412 PMCID： PMC4993926 DOI： 10.1016/j.chom.2016.07.004
Source DB: PubMed Journal: Cell Host Microbe ISSN： 1931-3128 Impact factor: 21.023